The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also ...
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvement ...
PYRUKYND is also approved for adults with PK deficiency in the U.S. and Europe, and a marketing application for PYRUKYND in thalassemia is currently under review by the European Commission. In the U.S ...
In beiden Studien reduzierte ALN1003 die Nahrungs- und Wasseraufnahme. Das Unternehmen merkte an, dass der Wirkstoff in Trinkwasserstudien einen dosisabhängigen Appetit- und Durstverlust verursachte, ...
Open-Label Study Demonstrates Durable Reduction in Oral Inflammation with Favorable Tolerability Profile at Interim Analysis HOUSTON, TEXAS / ACCESS Newswire / February 17, 2026 / Ainos, Inc. (NASDAQ: ...
The study is designed to enroll 12 client-owned cats diagnosed with FCGS across two dosing cohorts (6,000 IU and 12,000 IU administered orally three times per week for six weeks). The interim analysis ...
The BRAFTOVI combination regimen is the only approved targeted regimen for first-line BRAF-V600E mutant metastatic colorectal cancerPivotal results from the Phase 3 portion with mFOLFOX6 of the ...
Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the ...
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...
BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results